Industry Strength Score
11/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ENDRA LIFE SCIENCES INC (NDRA) Stock Price & Overview
NASDAQ:NDRA • US29273B5003
Current stock price
4.95 USD
+0.08 (+1.64%)
Last:
The current stock price of NDRA is 4.95 USD. Today NDRA is up by 1.64%. In the past month the price increased by 5.54%. In the past year, price decreased by -19.45%.
NDRA Key Statistics
52-Week Range2.9 - 11.96
Current NDRA stock price positioned within its 52-week range.
1-Month Range4.51 - 6.69
Current NDRA stock price positioned within its 1-month range.
- Market Cap
- 6.138M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -8.93
- Dividend Yield
- N/A
NDRA Stock Performance
Today
+1.64%
1 Week
-0.40%
1 Month
+5.54%
3 Months
+30.26%
Longer-term
6 Months -5.71%
1 Year -19.45%
2 Years -98.95%
3 Years -99.81%
5 Years -99.99%
10 Years N/A
NDRA Stock Chart
NDRA Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to NDRA. When comparing the yearly performance of all stocks, NDRA turns out to be only a medium performer in the overall market: it outperformed 49.69% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
NDRA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NDRA. The financial health of NDRA is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NDRA Earnings
Next Earnings DateMay 13, 2026
Last Earnings DateMar 31, 2026
PeriodQ4 / 2025
EPS Reported-$3.26
Revenue Reported
EPS Surprise -159.84%
Revenue Surprise %
NDRA Forecast & Estimates
7 analysts have analysed NDRA and the average price target is 27.54 USD. This implies a price increase of 456.36% is expected in the next year compared to the current price of 4.95.
Analysts
Analysts82.86
Price Target27.54 (456.36%)
EPS Next Y47.23%
Revenue Next YearN/A
NDRA Financial Highlights
Over the last trailing twelve months NDRA reported a non-GAAP Earnings per Share(EPS) of -8.93. The EPS increased by 98.54% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-7.03M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -182.35% | ||
| ROE | -310.93% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%57.6%
Sales Q2Q%N/A
EPS 1Y (TTM)98.54%
Revenue 1Y (TTM)N/A
NDRA Ownership
Ownership
Inst Owners6.41%
Shares1.24M
Float660.00K
Ins Owners37.34%
Short Float %7.32%
Short Ratio0.37
NDRA Industry Overview
NDRA operates in the Health Care Equipment sub-industry within the Health Care sector. This group contains 127 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
60/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
22%
Outperformed 22% of sub-industries
3 Month Rank
14%
Outperformed 14% of sub-industries
6 Month Rank
11%
Outperformed 11% of sub-industries
Industry Fundamentals & Breadth
- Members
- 127
- New Highs
- 2.4%
- New Lows
- 14.2%
- Average ROE
- 17.2%
- Average Profit Margin
- 20.3%
- Average Operating Margin
- 22.5%
- Average P/E
- 28.1
- Average Fwd P/E
- 27.3
- Average Debt/Equity
- 0.5
NDRA Competitors/Peers
The largest stocks on the US markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | 39.25 | 162.529B | ||
| ABT | ABBOTT LABORATORIES | 14.24 | 157.763B | ||
| SYK | STRYKER CORP | 17.41 | 120.688B | ||
| BSX | BOSTON SCIENTIFIC CORP | 14.31 | 85.619B | ||
| EW | EDWARDS LIFESCIENCES CORP | 24.9 | 48.141B | ||
| IDXX | IDEXX LABORATORIES INC | 38.32 | 44.539B | ||
| BDX | BECTON DICKINSON AND CO | 10.94 | 42.438B | ||
| RMD | RESMED INC | 16.7 | 31.148B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 10.74 | 27.761B | ||
| DXCM | DEXCOM INC | 20.18 | 22.918B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 9.11 | 15.956B | ||
| PEN | PENUMBRA INC | 63.83 | 12.837B | ||
| GMED | GLOBUS MEDICAL INC - A | 20.03 | 12.197B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NDRA
Company Profile
ENDRA Life Sciences, Inc. engages in the development of medical devices for accurate liver fat measurement for use in metabolic disease detection and GLP-1 drug eligibility and management. The company is headquartered in Ann Arbor, Michigan and currently employs 21 full-time employees. The company went IPO on 2017-06-28. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
Company Info
IPO: 2017-06-28
ENDRA LIFE SCIENCES INC
3600 Green Ct Ste 350
Ann Arbor MICHIGAN 48105 US
CEO: Francois Michelon
Employees: 21
Phone: 17343350468
ENDRA LIFE SCIENCES INC / NDRA FAQ
What does NDRA do?
ENDRA Life Sciences, Inc. engages in the development of medical devices for accurate liver fat measurement for use in metabolic disease detection and GLP-1 drug eligibility and management. The company is headquartered in Ann Arbor, Michigan and currently employs 21 full-time employees. The company went IPO on 2017-06-28. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
What is the current price of NDRA stock?
The current stock price of NDRA is 4.95 USD. The price increased by 1.64% in the last trading session.
Does ENDRA LIFE SCIENCES INC pay dividends?
NDRA does not pay a dividend.
What is the ChartMill technical and fundamental rating of NDRA stock?
NDRA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists NDRA stock?
NDRA stock is listed on the Nasdaq exchange.
Can you provide the market cap for ENDRA LIFE SCIENCES INC?
ENDRA LIFE SCIENCES INC (NDRA) has a market capitalization of 6.14M USD. This makes NDRA a Nano Cap stock.